D1 Striatal Medium Spiny Neurons In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
D1-expressing medium spiny neurons (D1-MSNs) are selectively vulnerable in Huntington's disease, contributing to the characteristic motor and cognitive symptoms. Unlike Parkinson's disease where D2-MSNs are primarily affected, HD shows early and severe loss of the direct pathway neurons. [1]
| Database | ID | Name | Confidence | [2]
|----------|----|------|------------| [3]
| Cell Ontology | CL:4030043 | matrix D1 medium spiny neuron | Medium | [4]
| Cell Ontology | CL:4030048 | striosomal D1 medium spiny neuron | Medium | [5]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4030043 | matrix D1 medium spiny neuron |
| Stage | D1-MSN Loss | Clinical Correlation |
|---|---|---|
| Premanifest | 20-30% | Subtle cognitive changes |
| Early | 40-50% | Chorea onset |
| Moderate | 60-70% | Movement disorders |
| Advanced | >80% | Severe |
mHTT →
↓ BDNF trafficking →
↓ TrkB signaling →
D1-MSN apoptosis
mHTT →
↓ PGC-1α →
Mitochondrial dysfunction →
Energy failure
The study of D1 Striatal Medium Spiny Neurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reiner A, Deng YP. Huntington's disease: die striatal medium spiny neurons first. Nat Rev Neurol. 2013. ↩︎
Raymond LA, Andre VM, Cepeda C, et al. Pathophysiology of Huntington's disease: synaptic dysfunction and mitochondrial deficits. Mol Neurobiol. 2012. ↩︎
Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 2004. ↩︎
Andre VM, Cepeda C, Levine MS. Dopamine and Huntington's disease: opportunities for therapeutic intervention. Neurodegener Dis. 2010. ↩︎
Whitemeer D, Czerkowicz J,凿 M, Pearce RKB, Smith T, Hallett PJ. BDNF deficiency and young-adult hippocampal excitability. Mol Cell Neurosci. 2010. ↩︎